New insights into hepatosplenic candidosis, a manifestation of chronic disseminated candidosis

Mycoses

Volumn 55, Issue 3, 2012, Pages

  Rammaert, B ^a   Desjardins, A ^a,b   Lortholary, O ^a,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b LAVAL UNIVERSITY   (Canada)

^c INSTITUT PASTEUR   (France)

Author keywords

Candida; Haematological neoplasms; Immune reconstitutxion inflammatory syndrome; Immunodepression; Invasive fungal disease; Liver

Indexed keywords

ALKALINE PHOSPHATASE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CHITIN; CHITOTRIOSIDASE; CORTICOSTEROID; DECTIN 1; FC RECEPTOR IIA; FLUCONAZOLE; FLUORODEOXYGLUCOSE F 18; GAMMA INTERFERON; GLUCAN; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 10; INTERLEUKIN 12P35; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; MANNOSE BINDING LECTIN 2; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VORICONAZOLE;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ADAPTIVE IMMUNITY; AGE; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBIOTIC PROPHYLAXIS; ANTIMICROBIAL THERAPY; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DISEASE DURATION; DRUG TREATMENT FAILURE; ECHOGRAPHY; FEVER; FUNGAL COLONIZATION; FUNGUS CULTURE; HEPATOMEGALY; HEPATOSPLENIC CANDIDOSIS; HOST PATHOGEN INTERACTION; HUMAN; HYPERTRANSAMINASEMIA; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTION RISK; INVASIVE CANDIDIASIS; LIVER BIOPSY; MORBIDITY; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RISK FACTOR; SPLENOMEGALY; TH17 CELL; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; HUMANS; LIVER DISEASES; SPLENIC DISEASES;

EID: 84859941522     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2012.02182.x     Document Type: Article

References (91)

1. Karthaus M, Hebart H, Einsele H et al. Long-term survival in patients with acute leukemia and chronic disseminated candidiasis despite minimal antileukemic therapy. Haematologica 2006; 91: 1422-3.
2. Masood A, Sallah S. Chronic disseminated candidiasis in patients with acute leukemia: emphasis on diagnostic definition and treatment. Leuk Res 2005; 29: 493-501.
3. Sallah S, Wan JY, Nguyen NP, Vos P, Sigounas G. Analysis of factors related to the occurrence of chronic disseminated candidiasis in patients with acute leukemia in a non-bone marrow transplant setting: a follow-up study. Cancer 2001; 92: 1349-53.
4. Blade J, Lopez-Guillermo A, Rozman C et al. Chronic systemic candidiasis in acute leukemia. Ann Hematol 1992; 64: 240-4.
5. Sallah S, Semelka RC, Wehbie R, Sallah W, Nguyen NP, Vos P. Hepatosplenic candidiasis in patients with acute leukaemia. Br J Haematol 1999; 106: 697-701.
6. Kontoyiannis DP, Luna MA, Samuels BI, Bodey GP. Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis. Infect Dis Clin North Am 2000; 14: 721-39.
7. Anttila VJ, Ruutu P, Bondestam S et al. Hepatosplenic yeast infection in patients with acute leukemia: a diagnostic problem. Clin Infect Dis 1994; 18: 979-81.
8. Pestalozzi BC, Krestin GP, Schanz U, Jacky E, Gmür J. Hepatic lesions of chronic disseminated candidiasis may become invisible during neutropenia. Blood 1997; 90: 3858-64.
9. Segal BH, Herbrecht R, Stevens DA et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47: 674-83.
10. Sallah S, Semelka R, Kelekis N, Worawattanakul S, Sallah W. Diagnosis and monitoring response to treatment of hepatosplenic candidiasis in patients with acute leukemia using magnetic resonance imaging. Acta Haematol 1998; 100: 77-81.
11. Rossetti F, Brawner DL, Bowden R et al. Fungal liver infection in marrow transplant recipients: prevalence at autopsy, predisposing factors, and clinical features. Clin Infect Dis 1995; 20: 801-11.
12. Halkic N, Ksontini R. Images in clinical medicine. Hepatosplenic candidiasis. N Engl J Med 2007; 356: e4.
13. Rudolph J, Rodenwaldt J, Ruhnke M, Hamm B, Kopka L. Unusual enhancement pattern of liver lesions in hepatosplenic candidiasis. Acta Radiol 2004; 45: 499-503.
14. Semelka RC, Shoenut JP, Greenberg HM, Bow EJ. Detection of acute and treated lesions of hepatosplenic candidiasis: comparison of dynamic contrast-enhanced CT and MR imaging. J Magn Reson Imaging 1992; 2: 341-5.
15. Anttila VJ, Lamminen AE, Bondestam S et al. Magnetic resonance imaging is superior to computed tomography and ultrasonography in imaging infectious liver foci in acute leukaemia. Eur J Haematol 1996; 56: 82-7.
16. Poeppel TD, Krause BJ, Heusner TA, Boy C, Bockisch A, Antoch G. PET/CT for the staging and follow-up of patients with malignancies. Eur J Radiol 2009; 70: 382-92.
17. Israel O, Keidar Z. PET/CT imaging in infectious conditions. Ann N Y Acad Sci 2011; 1228: 150-66.
18. Teyton P, Baillet G, Hindié E et al. Hepatosplenic candidiasis imaged with F-18 FDG PET/CT. Clin Nucl Med 2009; 34: 439-40.
19. Hot A, Maunoury C, Poiree S et al. Diagnostic contribution of positron emission tomography with [18F]fluorodeoxyglucose for invasive fungal infections. Clin Microbiol Infect 2011; 17: 409-17.
20. Anttila VJ, Färkkilä M, Jansson SE et al. Diagnostic laparoscopy in patients with acute leukemia and suspected hepatic candidiasis. Eur J Clin Microbiol Infect Dis 1997; 16: 637-43.
21. Girmenia C, Martino P, De Bernardis F, Boccanera M, Cassone A. Lack of circulating Candida mannoprotein antigen in patients with focal hepatosplenic candidiasis. J Med Microbiol 2004; 53: 103-6.
22. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
23. Letterio JJ, Lehrnbecher T, Pollack G, Walsh TJ, Chanock SJ. Invasive candidiasis stimulates hepatocyte and monocyte production of active transforming growth factor beta. Infect Immun 2001; 69: 5115-20.
24. Netea MG, Brown GD, Kullberg BJ, Gow NAR. An integrated model of the recognition of Candida albicans by the innate immune system. Nat Rev Microbiol 2008; 6: 67-78.
25. Lamoth F, Cruciani M, Mengoli C et al. β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis 2012; 54: 633-43.
26. Ostrosky-Zeichner L, Alexander BD, Kett DH et al. Multicenter clinical evaluation of the (1, 3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41: 654-9.
27. Senn L, Robinson JO, Schmidt S et al. 1, 3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2008; 46: 878-85.
28. Kondori N, Edebo L, Mattsby-Baltzer I. Circulating beta (1-3) glucan and immunoglobulin G subclass antibodies to Candida albicans cell wall antigens in patients with systemic candidiasis. Clin Diagn Lab Immunol 2004; 11: 344-50.
29. Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis 2011; 52: 750-70.
30. Ellis M, Al-Ramadi B, Bernsen R, Kristensen J, Alizadeh H, Hedstrom U. Prospective evaluation of mannan and anti-mannan antibodies for diagnosis of invasive Candida infections in patients with neutropenic fever. J Med Microbiol 2009; 58: 606-15.
31. Sendid B, Caillot D, Baccouch-Humbert B et al. Contribution of the Platelia Candida-specific antibody and antigen tests to early diagnosis of systemic Candida tropicalis infection in neutropenic adults. J Clin Microbiol 2003; 41: 4551-8.
32. Sendid B, Poirot JL, Tabouret M et al. Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J Med Microbiol 2002; 51: 433-42.
33. Prella M, Bille J, Pugnale M et al. Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies. Diagn Microbiol Infect Dis 2005; 51: 95-101.
34. Sun H-Y, Chiu Y-S, Tang J-L, Wang J-L, Chang S-C, Chen Y-C. The usefulness of the Platelia Candida antigen in a patient with acute lymphocytic leukemia and chronic disseminated candidiasis. Med Mycol 2006; 44: 647-50.
35. Mikulska M, Calandra T, Sanguinetti M, Poulain D, Viscoli C. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care 2010; 14: R222.
36. Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol 2011; 49: 665-70.
37. Kirby A, Chapman C, Hassan C, Burnie J. The diagnosis of hepatosplenic candidiasis by DNA analysis of tissue biopsy and serum. J Clin Pathol 2004; 57: 764-5.
38. Vollmer T, Störmer M, Kleesiek K, Dreier J. Evaluation of novel broad-range real-time PCR assay for rapid detection of human pathogenic fungi in various clinical specimens. J Clin Microbiol 2008; 46: 1919-26.
39. Fleischhacker M, Schulz S, Jöhrens K et al. Diagnosis of chronic disseminated candidosis from liver biopsies by a novel PCR in patients with haematological malignancies. Clin Microbiol Infect 2011; URL [accessed on 13 February 2012].
40. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
41. Lopez-Berestein G, Fainstein V, Hopfer R et al. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis 1985; 151: 704-10.
42. Lopez-Berestein G, Bodey GP, Frankel LS, Mehta K. Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. J Clin Oncol 1987; 5: 310-7.
43. Kauffman CA, Bradley SF, Ross SC, Weber DR. Hepatosplenic candidiasis: successful treatment with fluconazole. Am J Med 1991; 91: 137-41.
44. Anaissie E, Bodey GP, Kantarjian H et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 1991; 91: 142-50.
45. Cornely OA, Lasso M, Betts R et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 2007; 60: 363-9.
46. Kontny U, Walsh TJ, Rossler J, Uhl M, Niemeyer CM. Successful treatment of refractory chronic disseminated candidiasis after prolonged administration of caspofungin in a child with acute myeloid leukemia. Pediatr Blood Cancer 2007; 49: 360-2.
47. Hübel K, Chemnitz J, Brochhagen HG, Cornely OA. Successful treatment of chronic disseminated candidiasis with caspofungin and itraconazole in a patient with progressive acute leukemia and prolonged neutropenia. Int J Hematol 2004; 79: 289-92.
48. Vehreschild JJ, Krüger K, Kurzai O, Wickenhauser C, Behringer K, Töx U, et al. Salvage therapy of refractory chronic disseminated candidiasis in a patient with acute myeloid leukaemia and secondary prophylaxis during allogeneic stem cell transplantation. Mycoses. 2006;49 Suppl 1:42-7.
49. Xu B, Guo X-T, Wei Y-Q, Meng F-Y, Liu Q-F, Zhou S-Y. A clinical study of chronic disseminated candidiasis in patients with acute leukemia. Zhonghua Nei Ke Za Zhi 2008; 47: 468-71.
50. Poynton CH, Barnes RA, Rees J. Interferon gamma and granulocyte-macrophage colony-stimulating factor for the treatment of hepatosplenic candidosis in patients with acute leukemia. Clin Infect Dis 1998; 26: 239-40.
51. Pappas PG, Rex JH, Sobel JD et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-89.
52. Legrand F, Lecuit M, Dupont B et al. Adjuvant corticosteroid therapy for chronic disseminated candidiasis. Clin Infect Dis 2008; 46: 696-702.
53. Saint-Faust M, Boyer C, Gari-Toussaint M et al. Adjuvant corticosteroid therapy in two children with hepatosplenic candidiasis-related IRIS. J Pediatr Hematol Oncol 2009; 31: 794-6.
54. Lortholary O, Fontanet A, Mémain N, Martin A, Sitbon K, Dromer F. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 2005; 19: 1043-9.
55. Breton G, Adle-Biassette H, Therby A et al. Immune reconstitution inflammatory syndrome in HIV-infected patients with disseminated histoplasmosis. AIDS 2006; 20: 119-21.
56. Perfect JR, Dismukes WE, Dromer F et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50: 291-322.
57. Peigne V, Dromer F, Elie C, Lidove O, Lortholary O, the French Mycosis Study Group. Imported AIDS-related Histoplasmosis in metropolitan France: a comparison of pre-HAART and HAART eras. Am J Trop Med Hyg 2011; 85: 934-41.
58. Chandesris M-O, Kelaidi C, Méchaï F et al. Granulocyte colony stimulating factor-induced exacerbation of fungus-related immune restoration inflammatory syndrome: a case of chronic disseminated candidiasis exacerbation. J Microbiol Immunol Infect 2010; 43: 339-43.
59. Chen C-Y, Chen Y-C, Tang J-L et al. Hepatosplenic fungal infection in patients with acute leukemia in Taiwan: incidence, treatment, and prognosis. Ann Hematol 2003; 82: 93-7.
60. Bjerke JW, Meyers JD, Bowden RA. Hepatosplenic candidiasis--a contraindication to marrow transplantation? Blood 1994; 84: 2811-4.
61. Walsh TJ, Whitcomb PO, Revankar SG, Pizzo PA. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer 1995; 76: 2357-62.
62. Bow EJ, Loewen R, Cheang MS, Schacter B. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis 1995; 21: 361-9.
63. Walsh TJ, Pizzo PA. Experimental gastrointestinal and disseminated candidiasis in immunocompromised animals. Eur J Epidemiol 1992; 8: 477-83.
64. Koh AY, Köhler JR, Coggshall KT, Van Rooijen N, Pier GB. Mucosal damage and neutropenia are required for Candida albicans dissemination. PLoS Pathog 2008; 4: e35.
65. Netea MG, Van Der Graaf CAA, Vonk AG, Verschueren I, Van Der Meer JWM, Kullberg BJ. The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J Infect Dis 2002; 185: 1483-9.
66. Marr KA, Balajee SA, Hawn TR et al. Differential role of MyD88 in macrophage-mediated responses to opportunistic fungal pathogens. Infect Immun 2003; 71: 5280-6.
67. Re F, Strominger JL. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem 2001; 276: 37692-9.
68. Netea MG, Sutmuller R, Hermann C et al. Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. J Immunol 2004; 172: 3712-8.
69. Poulain D, Jouault T. Candida albicans cell wall glycans, host receptors and responses: elements for a decisive crosstalk. Curr Opin Microbiol 2004; 7: 342-9.
70. Ferwerda G, Meyer-Wentrup F, Kullberg B-J, Netea MG, Adema GJ. Dectin-1 synergizes with TLR2 and TLR4 for cytokine production in human primary monocytes and macrophages. Cell Microbiol 2008; 10: 2058-66.
71. LeibundGut-Landmann S, Gross O, Robinson MJ et al. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol 2007; 8: 630-8.
72. van de Veerdonk FL, Marijnissen RJ, Kullberg BJ et al. The macrophage mannose receptor induces IL-17 in response to Candida albicans. Cell Host Microbe 2009; 5: 329-40.
73. Gross O, Gewies A, Finger K et al. Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature 2006; 442: 651-6.
74. Glocker E-O, Hennigs A, Nabavi M et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med 2009; 361: 1727-35.
75. Romani L. Immunity to Candida albicans: Th1, Th2 cells and beyond. Curr Opin Microbiol 1999; 2: 363-7.
76. Bozza S, Zelante T, Moretti S et al. Lack of Toll IL-1R8 exacerbates Th17 cell responses in fungal infection. J Immunol 2008; 180: 4022-31.
77. Zelante T, De Luca A, Bonifazi P et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol 2007; 37: 2695-706.
78. Sun H-Y, Singh N. Immune reconstitution inflammatory syndrome in non-HIV immunocompromised patients. Curr Opin Infect Dis 2009; 22: 394-402.
79. Müller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 251-61.
80. Lanternier F, Chandesris M-O, Poirée S et al. Cellulitis revealing a cryptococcosis-related immune reconstitution inflammatory syndrome in a renal allograft recipient. Am J Transplant 2007; 7: 2826-8.
81. Singh N, Lortholary O, Alexander BD et al. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis 2005; 40: 1756-61.
82. Singh N, Lortholary O, Alexander BD et al. Allograft loss in renal transplant recipients with Cryptococcus neoformans associated immune reconstitution syndrome. Transplantation 2005; 80: 1131-3.
83. Miceli MH, Maertens J, Buvé K et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: Proof of principle, description, and clinical and research implications. Cancer 2007; 110: 112-20.
84. Cadena J, Thompson GR, Ho TT, Medina E, Hughes DW, Patterson TF. Immune reconstitution inflammatory syndrome after cessation of the tumor necrosis factor alpha blocker adalimumab in cryptococcal pneumonia. Diagn Microbiol Infect Dis 2009; 64: 327-30.
85. Hage CA, Bowyer S, Tarvin SE, Helper D, Kleiman MB, Joseph Wheat L. Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy. Clin Infect Dis 2010; 50: 85-92.
86. Singh N, Perfect JR. Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis 2007; 7: 395-401.
87. Lamaris GA, Lewis RE, Chamilos G et al. Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis 2008; 198: 186-92.
88. Cheng VC, Yuen KY, Wong SS et al. Immunorestitution diseases in patients not infected with HIV. Eur J Clin Microbiol Infect Dis 2001; 20: 402-6.
89. Roilides E, Sein T, Schaufele R, Chanock SJ, Walsh TJ. Increased serum concentrations of interleukin-10 in patients with hepatosplenic candidiasis. J Infect Dis 1998; 178: 589-92.
90. Choi EH, Taylor JG, Foster CB et al. Common polymorphisms in critical genes of innate immunity do not contribute to the risk for chronic disseminated candidiasis in adult leukemia patients. Med Mycol 2005; 43: 349-53.
91. Choi EH, Foster CB, Taylor JG et al. Association between chronic disseminated candidiasis in adult acute leukemia and common IL4 promoter haplotypes. J Infect Dis 2003; 187: 1153-6.